Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Company continuing to work with the U.S. FDA on potential for accelerated approval pathwayNovavax intends to partner on both candidates to advance to filing and commercialization